Shanghai Pharmaceutical Group Biotherapy Technology

Shanghai Pharmaceutical Group Biotherapy Technology is a specialized subsidiary of Shanghai Pharma (SPH) dedicated to the development and commercialization of advanced cell therapies. The company primarily focuses on chimeric antigen receptor T-cell (CAR-T) treatments for hematological malignancies and solid tumors. It operates a significant R&D and GMP manufacturing base in Shanghai, designed to facilitate the transition of biotherapy candidates from the laboratory to clinical application. By integrating the industrial resources of its parent company with cutting-edge biotechnology, SPH Biotherapy aims to provide innovative and affordable immunotherapy solutions. Its lead programs include therapies targeting CD19 and BCMA, which are currently undergoing clinical evaluation in China.